Teva Pharmaceutical Industries Limited

XNYSHealth care

Last traded price · USD

$41.14

−1.84%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 4 Nov 2026, 15:21 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $41.91
Volume: 46,234
Day's high: —
Day's low: —

In brief

Teva Pharmaceutical Industries Limited is a health care company listed on the New York Stock Exchange, valued at about $47.98B.
Its shares closed at $41.91 on 3 Nov 2026, up 104.2% over the past year.
From India you can buy TEVA in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Teva Pharmaceutical Industries Limited (TEVA) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole TEVA share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade TEVA options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Set a 52-week high on 3 Nov 2026
Closed at $41.91 on 3 Nov 2026: 3.3% below the 52-week high of $43.34 (3 Nov 2026) and 84.6% above the low of $22.70 (5 Nov 2025).
Daily price bars, split-adjusted · as of 3 Nov 2026
Ahead of SPY and its sector fund XLV over 1 year
1 month: +5.7% (SPY −2.6%, XLV +9.9%). 3 months: +21.7% (SPY −2.2%, XLV +13.5%). 1 year: +104.2% (SPY +10.4%, XLV +27.4%). Price change to the 3 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: TEVA, SPY and XLV · as of 3 Nov 2026
Volume 1.9× its 30-session average on 3 Nov 2026
3 Nov 2026 volume of 11.7M shares was 1.9× the average of the 30 sessions before it (6.2M), as the price rose 3.0%. SPY traded 0.8× its own average that session.
Daily volume against a 30-session baseline · as of 3 Nov 2026
Above its 50- and 200-day averages
The 3 Nov 2026 close of $41.91 was 6.8% above its 50-day average ($39.25) and 20.9% above its 200-day average ($34.67). It has closed above the 200-day for 73 sessions, since 23 Jul 2026. The 50-day average crossed above the 200-day on 16 Sep 2025, 285 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 3 Nov 2026
28.1M shares sold short
28.1M shares were sold short at the 15 Oct 2026 settlement; covering them would take 3.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 3 Nov 2026 close

1 month+5.7%

6 months+16.9%

1 year+104.2%

5 years+346.3%

Newswire

About

Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Website

Notable moves

November 5, 2025
+20.23%
December 17, 2024
+26.47%
July 27, 2022
+28.37%

Teva Pharmaceutical Industries Limited

XNYSHealth care

Last traded price · USD

$41.14

−1.84%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 4 Nov 2026, 15:21 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $41.91
Volume: 46,234
Day's high: —
Day's low: —

In brief

Teva Pharmaceutical Industries Limited is a health care company listed on the New York Stock Exchange, valued at about $47.98B.
Its shares closed at $41.91 on 3 Nov 2026, up 104.2% over the past year.
From India you can buy TEVA in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Teva Pharmaceutical Industries Limited (TEVA) shares from India?

Do I need the price of a whole TEVA share to invest?

How much can I invest in US stocks in a year?

Can I trade TEVA options or futures?

Insights

Quotes run fifteen minutes behind.

Set a 52-week high on 3 Nov 2026
Closed at $41.91 on 3 Nov 2026: 3.3% below the 52-week high of $43.34 (3 Nov 2026) and 84.6% above the low of $22.70 (5 Nov 2025).
Daily price bars, split-adjusted · as of 3 Nov 2026
Ahead of SPY and its sector fund XLV over 1 year
1 month: +5.7% (SPY −2.6%, XLV +9.9%). 3 months: +21.7% (SPY −2.2%, XLV +13.5%). 1 year: +104.2% (SPY +10.4%, XLV +27.4%). Price change to the 3 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: TEVA, SPY and XLV · as of 3 Nov 2026
Volume 1.9× its 30-session average on 3 Nov 2026
3 Nov 2026 volume of 11.7M shares was 1.9× the average of the 30 sessions before it (6.2M), as the price rose 3.0%. SPY traded 0.8× its own average that session.
Daily volume against a 30-session baseline · as of 3 Nov 2026
Above its 50- and 200-day averages
The 3 Nov 2026 close of $41.91 was 6.8% above its 50-day average ($39.25) and 20.9% above its 200-day average ($34.67). It has closed above the 200-day for 73 sessions, since 23 Jul 2026. The 50-day average crossed above the 200-day on 16 Sep 2025, 285 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 3 Nov 2026
28.1M shares sold short
28.1M shares were sold short at the 15 Oct 2026 settlement; covering them would take 3.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 3 Nov 2026 close

1 month+5.7%

6 months+16.9%

1 year+104.2%

5 years+346.3%

Newswire

About

Website

Notable moves

November 5, 2025
+20.23%
December 17, 2024
+26.47%
July 27, 2022
+28.37%

Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited in brief

Set a 52-week high on 3 Nov 2026

Ahead of SPY and its sector fund XLV over 1 year

Volume 1.9× its 30-session average on 3 Nov 2026

Above its 50- and 200-day averages

28.1M shares sold short

Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited in brief

Set a 52-week high on 3 Nov 2026

Ahead of SPY and its sector fund XLV over 1 year

Volume 1.9× its 30-session average on 3 Nov 2026

Above its 50- and 200-day averages

28.1M shares sold short